JNJJanssen Research & Development, LLCRunning, no new patients
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
Urinary Bladder Neoplasms
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 220 (final count)
- Started
- Dec 18, 2020
- Main results expected
- Jul 3, 2025
- Fully finished
- Sep 30, 2027
- Results posted
- Jul 29, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Cohorts 1, 2, and 3: Overall Complete Response (CR) Rate
Measured over: From date of first dose up to clinical cut-off date 3rd July 2025 (up to 50 months)
Cohort 4: Disease-free Survival (DFS)
Measured over: From date of first dose up to clinical cut-off date 3rd July 2025 (up to 50 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04640623 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC